Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1846 results
July 2017
-
Press release
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first… -
Story Access to Healthcare
Women in Science: Fionnuala Doyle
Doyle describes the road to improving patient outcomes across Europe through the HARMONY Alliance.
-
Press release
Die Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer Produkte
Der Nettoumsatz liegt auf Vorjahresniveau (0% kWk[1], -2% USD), wobei die Wachstumstreiber die Einbussen durch Generika von Glivec/Gleevec wettmachen: Cosentyx (USD 490 Millionen, +90% kWk)… -
Press release
Les résultats du T2 confirment les prévisions de l'exercice 2017. Les très bons résultats du pipeline étayent le potentiel de plusieurs produits hautement novateurs
Chiffre d'affaires net comparable à celui du T2 de l'exercice précédent (0% tcc[1], -2% en USD), car les moteurs de croissance ont compensé l'impact des génériques de Gleevec/Glivec: Cosentyx (… -
Press release
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications… -
Press release
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be… -
Press release
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is… -
Story Discovery
A researcher seeks the roots of plants’ healing power
Deep in a forest in the West African country of Ghana, two men are searching for plants that they hope could ultimately provide a cure for some of the world’s deadliest diseases.
-
In The News
Increasing access to NCD treatments in Uganda
Novartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access. -
Press release
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to… -
Featured News
Alcon survey reveals that people are happier and more satisfied with their lives after cataract surgery